SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Entero Therapeutics, Inc. (Nasdaq – ENTO)
BALA CYNWYD – November 13, 2024 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Entero Therapeutics, Inc. (“Entero” or the “Company”) (Nasdaq – ENTO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the reverse merger of the Company with Journey Therapeutics, Inc. (“Journey”). Under the terms of the transaction, shareholders of Journey will acquire 99% of the equity of Entero.
The investigation concerns whether the Entero Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.
If you own shares of Entero stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.